Sheffield Childrens Hospital NHS Foundation Trust
Sheffield, Select, S11 9LE, United Kingdom
Location status: Recruiting
Recruiting
NCT Number: NCT07049042
Hypogonadotrophic Hypogonadism in Genetic Neurodevelopmental Conditions
Hypogonadism is the medical name for a condition in which levels of the hormones which control sexual development are lower than normal. There are dozens of different causes of hypogonadism. Many people with hypogonadism have a change in a gene. There are many genes that give instructions for the hormones important for sexual development. Changes in one of these genes that stops the gene from working, can cause hypogonadism. In some of these medical conditions, there are additional features such as learning problems. In this study we will search databases to find all the genetic conditions that can be associated with hypogonadism. We will ask a number of people with changes in certain genes, identified from our search, to come to our research clinic. We will ask them about their health and examine them for signs of hypogonadism. For some, we will take blood samples to test for hypogonadism. This project will help us understand how common hypogonadism is, in people with these genetic changes, which will help with their treatment.
Recruiting
Interested in participating?
Request InfoKey information
Conditions
Age range
0 year–99 year
Sex eligibility
All sexes
Study type
Observational
Primary location
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Pathogenic SNV or CNV in neurodevelopmental disorders gene of interest parent or carer consents to study
Exclusion criteria
parent or carer does not consent to study
Treatment and study plan
Primary outcomes
-
Measurement of FSH
Time frame: within 1 month of recruitment
Blood sample to measure FSH levels.
FSH (IU/l) reference range Male, female 0 - 1 month <22.0 Roche 24.01.2011 Male 1 month - 6 years <2.8 Roche 24.01.2011 Male 6 - 11 years <3.8 Roche 24.01.2011 Male 11 - 14 years <4.6 Roche 24.01.2011 Male 14 years + 1.5 - 12 Roche 24.01.2011 Females 1 month - 14 years 0 - 11 Roche 24.01.2011 Follicular phase 3.5 - 13 Roche 24.01.2011 Mid-cycle 4.7 - 22 Roche 24.01.2011 Luteal phase 1.7 - 7.7 Roc
-
Measurement of LH
Time frame: within 1 month of recruitmen
Blood sample to assay LH levels. LH (IU/l) reference range Males 0 - 1 year <3.2 Wiedemann Males 1 - 11 years <1.4 Roche 24.01.2011 Males 11 - 14 years <7.8 Roche 24.01.2011 Males 14 - 17 years 1.3 - 9.8 Roche 24.01.2011 Males 17 years + 1.7 - 8.6 Roche 24.01.2011 Females 0 - 6 years <0.5 Roche 24.01.2011 Females 6 - 11 years <3.1 Roche 24.01.2011 Females 11 - 14 years <11.9 Roche 24.01.2011 Follicular Phase 2.4 - 13 Roche 24.01.2011 Mid - cycle 14 - 96 Roche 24.01.2011 Luteal phase 1.0 - 11 Roche 24.01.2011 Females 60y + (post-menopausal) 7.7 - 59 Roche 24.01.2011
-
Measurement of testosterone.
Time frame: within 1 month of recruitment.
Blood assay of testosterone levels in males. Testosterone (nmol/l) Reference range Males, 6 months - 6 years <1.12 Roche 24.01.2011 Males 6 - 13 years <2.37 Roche 24.01.2011 Males 13 - 18 years 0.98 - 38.5 Roche 24.01.2011 Males 18 - 50 years 8.6 - 29 Roche 24.01.2011 Males 50 years + 6.7 - 25.7 Roche 24.01.2011 Females 0 - 1 month 0.7 - 2.2 Soldin 24.01.2011 Females 1 month - 10 years <0.4 Soldin 24.01.2011 Females 10 - 12 years <0.9 Soldin 24.01.2011 Females 12 years + 0.3 - 1.7 Roche 24.01.2011 Females 50 years + 0.1 - 1.4 Roche 24.01.2011
-
Physical examination for pubertal staging.
Time frame: within 1- month of recruitment.
Tanner staging standard exam (testicular volume, body hair development, breast development).
-
General medical examination.
Time frame: within 1 month of recruitment
Height & weight, dysmorphology exam. Full respiratory, cardiac and neurological exam.
-
Bone age from x-ray.
Time frame: within 1-month of recruitment.
X-ray assessment of bone age retrieved from medical notes (optional, only if done in routine clinical care previously).
-
Brain MRI
Time frame: within 1 month of recruitment
Result retrieved from medical records, optional only if done as part of routine care.
-
Gonadal ultrasound
Time frame: within 1-month of recruitment
gonadal ultrasound, optional, if done by usual care team
-
Serum oestradiol
Time frame: within 1 month of recruitment
Oestradiol (pmol/l) reference range Males 1 - 10 years 18.4 - 73.4 Roche 24.01.2011 Males aged 10 years + 41.4 - 159 Roche 07/09/2017 Females aged 1 - 10 years 22 - 99.1 Roche 24.01.2011 Follicular phase <91.8 - 854 Roche 02/08/2016 Ovulation phase 151 - 1461 Roche 02/08/2016 Luteal phase <91.8 - 1251 Roche 02/08/2016 Females post-menopausal <386 STH study 02/08/2016
-
Serum AMH
Time frame: within 1 month of recruitment
AntiMullerian Hormone (pmol/l) 2.5th, 5th , Median, 95th
, 97.5th 20 - 24 yr 8.7, 10.9, 28.6, 71.0, 83.6 Roche 01/06/2018 25 - 29 yr 6.4, 8.6, 23.6, 64.6, 70.3 Roche 01/06/2018 30 - 34 yr 4.1, 5.1, 20.0, 54.2, 58.0 Roche 01/06/2018 35 - 39 yr 1.1, 2.9, 14.2, 49.7, 53.5 Roche 01/06/2018 40 - 44 yr 0.419, 0.4, 6.3, 31.7, 39.1 Roche 01/06/2018 45 - 50 yr 0.07, 0.07, 1.39, 12.8, 19.3 Roche 01/06/2018
-
Serum thyroid function tests
Time frame: within 1 month of recruitment
Free T3 (pmol/l) reference ranges Males, females 0 - 6 days 2.7 - 9.7 Roche 24.01.2011 Males, females 6 days - 3 months 3.0 - 9.3 Roche 24.01.2011 Males, females 3 - 12 months 3.3 - 9.0 Roche 24.01.2011 Males, females 1 - 6 years 3.7 - 8.5 Roche 24.01.2011 Males, females 6 - 11 years 3.9 - 8.0 Roche 24.01.2011 Males, females 11 - 20 years 3.9 - 7.7 Roche 24.01.2011 Males, females 20 years + 3.1 - 6.8 Roche 24.01.2011 Pregnancy, first trimester 3.8 - 6.0 Roche 24.01.2011 Pregnancy, second trimester 3.2 - 5.5 Roche 24.01.2011 Pregnancy, third trimester 3.1 - 5.0 Roche 24.01.2011 Free T4 (pmol/l) Males, females 0 - 6 days 11.0 - 32.0 Roche 24.01.2011 Males, females 6 days - 3 months 11.5 - 28.3 Roche 24.01.2011 Males, females 3 - 12 months 11.9 - 25.6 Roche 24.01.2011 Males, females 1 year + 11.9 - 21.6 Roche 14.03.2023 Pregnancy, first trimester 12.1 - 19.6 Roche 24.01.2011 Pregnancy, second trimester 9.6 - 17 Roche 24.01.2011 Pregnancy, third trimester 8.4 - 15.6 Roche 24.01.2011
-
Serum IGF1 level
Time frame: within 1 month recruitment
GF-1 (µg/l) Males, 0 - 3 months No range (comment) 06.10.2020 Males, 3 - 6 months 12 - 94 Roche 06.10.2020 Males, 6 - 12 months 12 - 95 Roche 06.10.2020 Males, 1 year 12 - 96 Roche 06.10.2020 Males, 2 years 14 - 104 Roche 06.10.2020 Males, 3 years 19 - 116 Roche 06.10.2020 Males, 4 years 27 - 134 Roche 06.10.2020 Males, 5 years 37 - 156 Roche 06.10.2020 Males, 6 years 47 - 184 Roche 06.10.2020 Males, 7 years 58 - 216 Roche 06.10.2020 Males, 8 years 68 - 254 Roche 06.10.2020 Males, 9 years 77 - 296 Roche 06.10.2020 Males, 10 years 86 - 343 Roche 06.10.2020 Males, 11 years 94 - 392 Roche 06.10.2020 Males, 12 years 101 - 434 Roche 06.10.2020 Males, 13 years 108 - 467 Roche 06.10.2020 Males, 14 years 115 - 489 Roche 06.10.2020 Males, 15 years 120 - 501 Roche 06.10.2020 Males, 16 years 125 - 503 Roche 06.10.2020 Males, 17 years 129 - 495 Roche 06.10.2020 Males, 18 years 132 - 476 Roche 06.10.2020 Males, 19 years 134 - 450 Roche 06.10.2020 Males, 20 years 136 - 421 Roche 06.10.2020 Males, 2
-
Serum prolactin
Time frame: within 1-month recruitment
Males, females 0 - 1 year No range (comment) Males 1 year + 86 - 324 Roche 24.01.2011 Females 1 year + 102 - 496 Roche 24.01.2011
-
serum cortisol
Time frame: within 1 month recruitment
Cortisol (nmol/l) Neonates 50 - 300 Sippell et al 01.06.2012 Adults 6 - 10 am 4 - 8 pm
Random or 8.30-9.30 am:
Adrenal insufficiency unlikely (NB does not apply to sick patients with high index of suspicion)
Synacthen test (30 min cort):
Primary adrenal insufficiency unlikely 133 - 537 68 - 327
>/=350 >430 Wythenshawe In-house In-house 18.04.2016 21/12/2018 21/12/2018
-
serum ACTH
Time frame: within 1-month
ACTH, 7 am - 10 am (ng/l) 7.2 - 63.3 Roche 22/10/2018
Sponsors and collaborators
Lead sponsor
University of Sheffield
Other
Registry information
Important dates
- Study start
- 2025
- Primary completion
- 2029
- Study completion
- 2029
- First posted
- Jul 3, 2025
- Registry last updated
- Jul 3, 2025
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.